Literature DB >> 17510707

Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair.

Christopher B Little1, Clare T Meeker, Suzanne B Golub, Kate E Lawlor, Pamela J Farmer, Susan M Smith, Amanda J Fosang.   

Abstract

Aggrecan loss from cartilage in arthritis is mediated by aggrecanases. Aggrecanases cleave aggrecan preferentially in the chondroitin sulfate-2 (CS-2) domain and secondarily at the E(373) downward arrow(374)A bond in the interglobular domain (IGD). However, IGD cleavage may be more deleterious for cartilage biomechanics because it releases the entire CS-containing portion of aggrecan. Recent studies identifying aggrecanase-2 (ADAMTS-5) as the predominant aggrecanase in mouse cartilage have not distinguished aggrecanolysis in the IGD from aggrecanolysis in the CS-2 domain. We generated aggrecan knockin mice with a mutation that rendered only the IGD resistant to aggrecanases in order to assess the contribution of this specific cleavage to cartilage pathology. The knockin mice were viable and fertile. Aggrecanase cleavage in the aggrecan IGD was not detected in knockin mouse cartilage in situ nor following digestion with ADAMTS-5 or treatment of cartilage explant cultures with IL-1 alpha. Blocking cleavage in the IGD not only diminished aggrecan loss and cartilage erosion in surgically induced osteoarthritis and a model of inflammatory arthritis, but appeared to stimulate cartilage repair following acute inflammation. We conclude that blocking aggrecanolysis in the aggrecan IGD alone protects against cartilage erosion and may potentiate cartilage repair.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17510707      PMCID: PMC1866253          DOI: 10.1172/JCI30765

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  62 in total

Review 1.  MMPs and ADAMTSs: functional studies.

Authors:  Carl R Flannery
Journal:  Front Biosci       Date:  2006-01-01

2.  Shear and compression differentially regulate clusters of functionally related temporal transcription patterns in cartilage tissue.

Authors:  Jonathan B Fitzgerald; Moonsoo Jin; Alan J Grodzinsky
Journal:  J Biol Chem       Date:  2006-06-16       Impact factor: 5.157

3.  The cleavage of biglycan by aggrecanases.

Authors:  L I Melching; W D Fisher; E R Lee; J S Mort; P J Roughley
Journal:  Osteoarthritis Cartilage       Date:  2006-06-30       Impact factor: 6.576

4.  Recombinant human aggrecan G1-G2 exhibits native binding properties and substrate specificity for matrix metalloproteinases and aggrecanase.

Authors:  F A Mercuri; K J Doege; E C Arner; M A Pratta; K Last; A J Fosang
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

5.  Matrix metalloproteinases are not essential for aggrecan turnover during normal skeletal growth and development.

Authors:  Christopher B Little; Clare T Meeker; Rosalind M Hembry; Natalie A Sims; Kate E Lawlor; Sue B Golub; Karena Last; Amanda J Fosang
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

6.  ADAMTS-1-knockout mice do not exhibit abnormalities in aggrecan turnover in vitro or in vivo.

Authors:  Chris B Little; Laureane Mittaz; Daniele Belluoccio; Fraser M Rogerson; Ian K Campbell; Clare T Meeker; John F Bateman; Melanie A Pritchard; Amanda J Fosang
Journal:  Arthritis Rheum       Date:  2005-05

7.  ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro.

Authors:  Heather Stanton; Fraser M Rogerson; Charlotte J East; Suzanne B Golub; Kate E Lawlor; Clare T Meeker; Christopher B Little; Karena Last; Pamela J Farmer; Ian K Campbell; Anne M Fourie; Amanda J Fosang
Journal:  Nature       Date:  2005-03-31       Impact factor: 49.962

8.  Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis.

Authors:  Sonya S Glasson; Roger Askew; Barbara Sheppard; Brenda Carito; Tracey Blanchet; Hak-Ling Ma; Carl R Flannery; Diane Peluso; Kim Kanki; Zhiyong Yang; Manas K Majumdar; Elisabeth A Morris
Journal:  Nature       Date:  2005-03-31       Impact factor: 49.962

Review 9.  The ADAMTS metalloproteinases.

Authors:  Sarah Porter; Ian M Clark; Lara Kevorkian; Dylan R Edwards
Journal:  Biochem J       Date:  2005-02-15       Impact factor: 3.857

Review 10.  ADAMTS proteinases: a multi-domain, multi-functional family with roles in extracellular matrix turnover and arthritis.

Authors:  Gavin C Jones; Graham P Riley
Journal:  Arthritis Res Ther       Date:  2005-06-21       Impact factor: 5.156

View more
  67 in total

1.  Role of Sp1 transcription factor in Interleukin-1-induced ADAMTS-4 (aggrecanase-1) gene expression in human articular chondrocytes.

Authors:  Judith Sylvester; Rasheed Ahmad; Muhammad Zafarullah
Journal:  Rheumatol Int       Date:  2011-11-08       Impact factor: 2.631

Review 2.  The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis.

Authors:  Carla R Scanzello; Neal K Moskowitz; Allan Gibofsky
Journal:  Curr Pain Headache Rep       Date:  2007-12

Review 3.  An emerging role for Toll-like receptors at the neuroimmune interface in osteoarthritis.

Authors:  Rachel E Miller; Carla R Scanzello; Anne-Marie Malfait
Journal:  Semin Immunopathol       Date:  2019-10-14       Impact factor: 9.623

Review 4.  ADAMTS proteins in human disorders.

Authors:  Timothy J Mead; Suneel S Apte
Journal:  Matrix Biol       Date:  2018-06-06       Impact factor: 11.583

5.  Adamts5-/- Mice Exhibit Altered Aggrecan Proteolytic Profiles That Correlate With Ascending Aortic Anomalies.

Authors:  Loren E Dupuis; E Lockett Nelson; Brittany Hozik; Sarah C Porto; Alexandra Rogers-DeCotes; Amanda Fosang; Christine B Kern
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-08-01       Impact factor: 8.311

Review 6.  Extracellular matrix and pathogenic mechanisms in osteoarthritis.

Authors:  Tim Hardingham
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

Review 7.  Lessons from animal models of osteoarthritis.

Authors:  Wim B van den Berg
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

8.  Novel selective MMP-13 inhibitors reduce collagen degradation in bovine articular and human osteoarthritis cartilage explants.

Authors:  Dorothea Piecha; Jürgen Weik; Heike Kheil; Gabriele Becher; Andreas Timmermann; Andreas Jaworski; Maren Burger; Michael W Hofmann
Journal:  Inflamm Res       Date:  2009-11-10       Impact factor: 4.575

9.  Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development.

Authors:  C B Little; A Barai; D Burkhardt; S M Smith; A J Fosang; Z Werb; M Shah; E W Thompson
Journal:  Arthritis Rheum       Date:  2009-12

Review 10.  Anti-ADAMTS5 monoclonal antibodies: implications for aggrecanase inhibition in osteoarthritis.

Authors:  Suneel S Apte
Journal:  Biochem J       Date:  2016-01-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.